Third Rock, Harvard cuts, Akeso, Summit
Need to keep on high of the science and politics driving biotech right now? Join to get our biotech publication in your inbox.
Good morning. My colleague Allison DeAngelis has been working for months on our annual VC rankings report. Learn on for what she discovered.
Third Rock tops STAT’s annual VC rating
Amongst biotech enterprise capital companies, Third Rock Enterprise has generated the perfect returns on its investments in 2024 and 2025, in line with STAT’s annual VC rankings report.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
